Brief: Reig Jofre's JV Reaches License Deal With Intas Pharmaceuticals For Biosimilars
02/11/2022 08:22
Nov 2 (Reuters) - Laboratorio Reig Jofre SA RJFE.MC :
* GLOBAL LICENSE AGREEMENT REACHED BY REIG JOFRE’S
JOINT-VENTURE,
SYNA THERAPEUTICS
* LICENSE AGREEMENT WITH BIOPHARMACEUTICAL COMPANY INTAS
PHARMACEUTICALS LTD. FOR COMMERCIALIZATION OF BIOSIMILAR
MEDICINE LB0702
* ACCORDING TO TERMS OF DEAL, SYNA THERAPEUTICS TO BEGIN IN
2023
CLINICAL TRIALS FOR ITS BIOSIMILAR LB-07802 TO TREAT PATHOLOGIES
IN FIELD OF HEMATOLOGY
* JOINT-VENTURE SYNA THERAPEUTICS IS 50% OWNED BY LEANBIO
AND REIG
JOFRE, FOR DEVELOPMENT OF BIOPHARMACEUTICAL PRODUCTS IN FIELD OF
BIOSIMILARS AND INNOVATIVE MOLECULES
* INTAS PHARMACEUTICAL TO COVER THE MARKETING COSTS
* TO CONTRIBUTE TO DEVELOPMENT AND STABILIZATION OF FINAL
PHARMACEUTICAL PRODUCT, BESIDES OFFERING ITS GLOBAL PRODUCTION
CAPACITY IN NEW DEVELOPMENT AND SPECIALIZED PRODUCTION CENTER IN
BARCELONA
Source text for Eikon: ID:nCNM1w3VGS
Further company coverage: RJFE.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))